Latest News in the pharma Industry

Research & Development

Positive Phase I/II interim data of Bimatoprost sustained-release implant for IOP therapy in glaucoma

Positive Phase I/II interim data of Bimatoprost sustained-release implant for IOP therapy in glaucoma

16 Nov 2015

Bimatoprost SR is a biodegradable, intracameral implant providing slow release of bimatoprost and is a differentiated approach to treat glaucoma beyond conventional daily eye drop treatments because it is a non-daily treatment administered by a physici...

Read more 
Allergan presents data at the 2015 American Academy of Ophthalmology Annual Meeting in Las Vegas

Allergan presents data at the 2015 American Academy of Ophthalmology Annual Meeting in Las Vegas

13 Nov 2015

Five oral presentations include “Long-Term Response to Anti-VEGF Therapy for DME Can be Predicted After 3 Injections — An Analysis of Protocol I Data”.

Read more 
FDA approves Roche’s Cotellic in combination with Zelboraf in advanced melanoma

FDA approves Roche’s Cotellic in combination with Zelboraf in advanced melanoma

12 Nov 2015

FDA approval underscores the important role of targeted medicines to help people with BRAF V600 mutation-positive advanced melanoma.

Read more 
Concert Pharmaceuticals initiates Phase I multiple ascending dose trial with CTP-656 for cystic fibrosis

Concert Pharmaceuticals initiates Phase I multiple ascending dose trial with CTP-656 for cystic fibrosis

12 Nov 2015

A novel, potentially disease-modifying treatment for cystic fibrosis for use as monotherapy as well as in combination with other CFTR modulators.

Read more 
Amgen presents detailed results from Phase III study demonstrating clinical equivalence of biosimilar candidate ABP 501 with adalimumab

Amgen presents detailed results from Phase III study demonstrating clinical equivalence of biosimilar candidate ABP 501 with adalimumab

12 Nov 2015

First completed Phase III study of adalimumab biosimilar in the treatment of patients with moderate-to-severe RA.

Read more 
Regeneron and Sanofi announce new Praluent injection analyses presented at AHA scientific sessions 2015

Regeneron and Sanofi announce new Praluent injection analyses presented at AHA scientific sessions 2015

11 Nov 2015

74% of patients reached their LDL cholesterol goals on 75 mg dose; Of the remaining patients whose dose was adjusted to 150 mg, most achieved their goal.

Read more 
Teva granted Breakthrough Therapy Designation for SD-809 by FDA

Teva granted Breakthrough Therapy Designation for SD-809 by FDA

9 Nov 2015

SD-809 — a much-needed treatment option for the tardive dyskinesia patient population.

Read more 
FDA accepts Amgen's NDA for novel intravenous calcimimetic etelcalcetide

FDA accepts Amgen's NDA for novel intravenous calcimimetic etelcalcetide

9 Nov 2015

If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously.

Read more 
Real-world analysis of more than 44,000 patients reinforces safety and effectiveness of Pradaxa in routine clinical care

Real-world analysis of more than 44,000 patients reinforces safety and effectiveness of Pradaxa in routine clinical care

9 Nov 2015

New data show Pradaxa reduced stroke risk and major bleeding compared to warfarin in patients with non-valvular atrial fibrillation.

Read more 
High quality specific ChIP-validated antibodies

High quality specific ChIP-validated antibodies

9 Nov 2015

The company now offeres the first nine antibodies in its Validated Antibody programme which are H3, RNA pol II (S), RNA pol II (S5), H3K9me3, 5mC, AcH3, AcH4, AR and Sin3a

Read more 
Sanofi Pasteur reveals its research on a ”universal” influenza vaccine

Sanofi Pasteur reveals its research on a ”universal” influenza vaccine

9 Nov 2015

The vaccines division of Sanofi presents at the World Vaccine Congress in Spain.

Read more 
Detailed results demonstrate baricitinib superiority to adalimumab in improving signs and symptoms of RA

Detailed results demonstrate baricitinib superiority to adalimumab in improving signs and symptoms of RA

8 Nov 2015

Patient-reported pain, joint stiffness, fatigue and physical function scores significantly improved with baricitinib compared to adalimumab.

Read more